Clinical trials: Disorders of Breast
Breast Carcinoma, Metastatic Breast Cancer
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
- Conditions
- Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology
- Trial name
- NCT03970967
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Breast Neoplasms
Low Dose Tomosynthesis Compared to Traditional Tomosynthesis
This study aims to evaluate image quality of a low-dose tomosynthesis system versus a comparator. Subjects will undergo a four-view tomosynthesis examination with the comparator and with the study device, and images will be…
- Trial name
- NCT02771444
- Testing
- Tomo Assessment
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Philips Digital Mammography Sweden AB
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Advanced Solid Tumors
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency.
- Trial name
- NCT06183736
- Testing
- CVL237 tablets
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Breast Cancer, Lung Cancer
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer
- Trial name
- D-1MT (NCT00739609)
- Testing
- 1-methyl-D-tryptophan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- NewLink Genetics Corporation
Locally Recurrent and Metastatic Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel…
- Trial name
- NCT00322400
- Testing
- Docetaxel, Paclitaxel, AMG 706
- Volunteers
- 46 people
- Sponsor
- Amgen
Breast Cancer, Head and Neck Cancer
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: Have benefited from ongoing study treatment as determined by the study doctor in a…
- Trial name
- NCT05226871
- Testing
- Palbociclib, Cetuximab, Fulvestrant
- Where
- 23 sites in United States, China and 5 more
- Volunteers
- 35 people
- Sponsor
- Pfizer
Breast Cancer
Patient's Anastrozole Compliance to Therapy Programme
Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS).
- Trial name
- PACT (NCT00555867)
- Testing
- Anastrozole
- Volunteers
- 4,923 people
- Sponsor
- AstraZeneca
Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer.
- Trial name
- NCT05645536
- Testing
- TOL2506, Tamoxifen, Letrozole tablets
- Where
- 46 sites in United States, Argentina and 4 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Breast Cancer
Identification and Semi-Quantification of Ki-67 Protein Expression Status
The purpose of the study is the identification and semi-quantification of Ki-67 protein expression level in breast cancer tissues by the GenASIs GoPth system as compared to manual reading of the same slides.
- Trial name
- NCT02654457
- Testing
- Women with Breast Cancer
- Volunteers
- 3 people
- Sponsor
- Applied Spectral Imaging Ltd.
Breast Neoplasm, Colon Neoplasm
A Study of MLN8054 in Patients With Advanced Solid Tumors
The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and…
- Conditions
- Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
- Trial name
- NCT00249301
- Testing
- MLN8054
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast…
- Trial name
- NCT04094519
- Testing
- enzalutamide, digoxin, rosuvastatin
- Where
- Moldova
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Breast Cancer
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg.
- Trial name
- NCT04175171
- Testing
- Coprelotamab Injection, Trastuzumab Injection
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Breast Cancer
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05160545
- Testing
- GNC-035
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects
- Trial name
- NCT03845907
- Testing
- Gen 1B, Gen 1
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Seno Medical Instruments Inc.
Breast Neoplasms
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or…
- Trial name
- SUN 1064 (NCT00393939)
- Testing
- Sunitinib malate, Taxotere
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 594 people
- Sponsor
- Pfizer
Breast Cancer, Hormone-receptor-positive Breast Cancer
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
This first-in-human, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of PRT13722, an oral KAT6A protein degrader, in adults with locally…
- Conditions
- Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer
- Trial name
- NCT07905001
- Testing
- PRT13722, Fulvestrant, Abemaciclib
- Volunteers
- 242 people
- Sponsor
- Prelude Therapeutics Incorporated
Breast Cancer
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel…
- Trial name
- SAPPHIRE (NCT02019277)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 13 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous…
- Trial name
- NCT00928330
- Testing
- GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.